Current and potential treatment options for hyperphosphatemia

References

• Knochel JP. Phosphorus. In: Shils ME, Shike M, Ross AC, et al., edited by. Modern nutrition in health and disease. 10th ed. Baltimore: Lippincott Williams & Wilkins; 2006. p. 211–222.
   Google Scholar
• Ramirez J, Emmett M, White M, et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30:753–759.
   PubMed Web of Science ®Google Scholar
• Villa-Bellosta R, Ravera S, Sorribas V, et al. The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol. 2009;296(4):F691–9.
   PubMed Web of Science ®Google Scholar
• Sabbagh Y, O’Brien SP, Song W, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol. 2009;20(11):2348–2358.
   PubMed Web of Science ®Google Scholar
• Kopple J, Coburn J. Metabolic studies of low protein diets in uremia: II. Calcium, phosphorus and magnesium. Medicine (Baltimore). 1973;52:597–607.
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutierrez O, Shah A, et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol. 2008;19:615–623.
   PubMed Web of Science ®Google Scholar
• Craver L, Marco M, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5: achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22:1171–1176.
   PubMed Web of Science ®Google Scholar
• Cornelis T, van der Sande FM, Eloot S, et al. Acute hemodynamic response and uremic toxin removal in conventional and extended hemodialysis and hemodiafiltration: a randomized crossover study. Am J Kidney Dis. 2014;64(2):247–256.
   PubMed Web of Science ®Google Scholar
• Nadkarni GN, Uribarri J. Phosphorus and the kidney: what is known and what is needed. Adv Nutr. 2014;5:98–103.
   PubMed Web of Science ®Google Scholar
• Da J, Xie X, Wolf M, et al. Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies. Am J Kidney Dis. 2015;66:258–265.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Ruggenenti P, Perna A, et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22(10):1923–1930.
   PubMed Web of Science ®Google Scholar
• Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clinical J Am Soc Nephrol. 2010;5–12:2251–2257.
   Web of Science ®Google Scholar
• Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71–5:438–441.
   Web of Science ®Google Scholar
• Tentori F, Blayney M, Albert J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52(3):519–530.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. Jama. 2011;305:1119.
   PubMed Web of Science ®Google Scholar
• National kidney foundation: K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.
   PubMed Web of Science ®Google Scholar
• KDIGO. clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD–MBD). Kidney Int. 2009;113(Suppl):1–130.
   Google Scholar
• Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–884.
   PubMed Web of Science ®Google Scholar
• Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol. 1999;10:2426–2439.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Lakatua JD, Ma JZ, et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–961.
   PubMed Web of Science ®Google Scholar
• Haring B, Selvin E, Liang M, et al. Dietary protein sources and risk for incident chronic kidney disease: results from the atherosclerosis risk in communities (ARIC) study. J Ren Nutr. 2017;27:233–242.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy. Am J Clin Nutr. 2013;97:1163–1177.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei G, Jalili T, et al. The associations of plant protein intake with all-cause mortality in CKD. Am J Kidney Dis. 2016;67:423–430.
   PubMed Web of Science ®Google Scholar
• Bover J, Ureña-Torres P, Lloret MT, et al. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Opin Pharmacother. 2016;17(10):1363–1373.
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315(3):157.
   PubMed Web of Science ®Google Scholar
• Caravaca F, Santos I, Cubero J, et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron. 1992;60(4):423–427.
   PubMed Web of Science ®Google Scholar
• Pflanz S, Henderson IS, McElduff N, et al. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant. 1994;9(8):1121–1124.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Dusso A, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol. 2001;12(11):2511–2516.
   PubMed Web of Science ®Google Scholar
• Guillot A, Hood V, Runge C, et al. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982;30(2):114–117.
   PubMed Web of Science ®Google Scholar
• Delmez J, Kelber J, Norword K, et al. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996;49(1):163–167.
   PubMed Web of Science ®Google Scholar
• de Francisco A, Leidig M, Covic A, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25(11):3707–3717.
   PubMed Web of Science ®Google Scholar
• Jamal S, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. The Lancet. 2013;382(9900):1268–1277.
   PubMed Web of Science ®Google Scholar
• Pai A, Shepler B. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy. 2009;29(5):554–561.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125–1130.
   PubMed Web of Science ®Google Scholar
• De Santo N, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol. 2006;19(suppl 9):S108–14.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant. 2009;24(1):278–285.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934–942.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother. 2014;13(5):551–561.
   Google Scholar
• Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant. 2004;19(10):2630–2633.
   PubMed Web of Science ®Google Scholar
• Madan P, Bhayana S, Chandra P, et al. Lower gastrointestinal bleeding: association with sevelamer use. World J Gastroenterol. 2008;14(16):2615–2616.
   PubMed Web of Science ®Google Scholar
• Wills M, Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. The Lancet. 1983;322(8340):29–34.
   Google Scholar
• Damment S, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clinical Pharmacokinetics. 2008;47(9):553–563.
   PubMed Web of Science ®Google Scholar
• D’Haese P, Spasovski G, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003;63:S73–S78.
   Web of Science ®Google Scholar
• Yabuki AK, Shibaa E, Harada H, et al. Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: analysis of surgically excised specimens and review of the literature. Pathol – Res Pract. 2016;212:919–926.
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005;68:2809.
   PubMed Web of Science ®Google Scholar
• Behets G, Verberckmoes S, Oste L, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int. 2005;67:1830–1836.
   PubMed Web of Science ®Google Scholar
• Sprague S, Abboud H, Qiu P, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009;4:178.
   PubMed Web of Science ®Google Scholar
• Persy V, Behets G, Bervoets A, et al. Lanthanum: a safe phosphate binder. Semin Dial. 2006;19:195.
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Martin K, Fishbane S, et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol. 2008;3:1437.
   PubMed Web of Science ®Google Scholar
• Lanz M, Baldischweiler KB, Schill J, et al. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2013;40(12):1623–1631.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Gaillard S, Rakov V, et al. The iron based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(4):251–258.
   PubMed Web of Science ®Google Scholar
• Covic AC, Floege J, Ketteler M, et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplan. 2016.
   Web of Science ®Google Scholar
• Yokoyama K, Akiba T, Fukagawa M, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant. 2014;29:1053–1060.
   PubMed Web of Science ®Google Scholar
• Lee CT, Wu IW, Chiang SS, et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol. 2015;28(1):105–113.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. J Am Soc Nephrol. 2017;28(6):1851–1858.
   PubMed Web of Science ®Google Scholar
• Molitoris B, Froment D, Mackenzie T, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989;36(6):949–953.
   PubMed Web of Science ®Google Scholar
• Alfrey AC. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit. 1993;15:593–597.
   PubMed Web of Science ®Google Scholar
• Sampathkumar K. Niacin and analogs for phosphate control in dialysis–perspective from a developing country. Int Urol Nephrol. 2009;41:913–918.
   PubMed Web of Science ®Google Scholar
• Kirkland JB. Niacin status impacts chromatin structure. J Nutr. 2009;139:2397–2401.
   PubMed Web of Science ®Google Scholar
• Schiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23:1691–1700.
   PubMed Web of Science ®Google Scholar
• Boden W, Probstfield J, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Block G, Rosenbaum D, Leonsson-Zachrisson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28:1933–1942.
   PubMed Web of Science ®Google Scholar
• Labonté E, Carreras C, Leadbetter M, et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol. 2015;26:1138–1149.
   PubMed Web of Science ®Google Scholar
• Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885.
   PubMed Web of Science ®Google Scholar
• Foley R, Collins A, Herzog C, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20:397–404.
   PubMed Web of Science ®Google Scholar
• Block G, Klassen P, Lazarus J, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218.
   PubMed Web of Science ®Google Scholar
• McGovern A, De Lusignan S, Van Vlymen J, et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013;8(9):e74996.
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kido R, Komaba H, et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63:979–987.
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617.
   PubMed Web of Science ®Google Scholar
• Block G, Wheeler D, Persky M, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–1415.
   PubMed Web of Science ®Google Scholar
• Sherman R, Ravella S, Kapoian T. A dearth of data: the problem of phosphorus in prescription medications. Kidney Int. 2015;87:1097–1099.
   PubMed Web of Science ®Google Scholar
• Cupisti A, Moriconi D, D’Alessandro C, et al. The extra-phosphate intestinal load from medications: is it a real concern? J Nephrol. 2016;29:857–862.
   PubMed Web of Science ®Google Scholar
• Cannata-Andıa J, Fernandez-Martın J, Locatelli F, et al. Use of phosphate binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5):998–1008.
   PubMed Web of Science ®Google Scholar
• Lopes A, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis. 2012;60(1):90–101.
   PubMed Web of Science ®Google Scholar
• Cannata-Andia J, Fernández-Martín J, Zoccali C, et al. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). J Nephrol. 2008;21(3):290–298.
   PubMed Web of Science ®Google Scholar
• Drüeke T, Massy Z. Lowering expectations with niacin treatment for CKD-MBD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):6–8.
   PubMed Web of Science ®Google Scholar
• Malhotra R, Katz R, Hoofnagle A, et al. The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol. 2018;13(1):36–44.
   PubMed Web of Science ®Google Scholar
• Diaz-Tocados JM, Peralta-Ramirez A, Rodríguez-Ortiz ME, et al. Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int. 2017;92(5):1084–1099.
   PubMed Web of Science ®Google Scholar
• Tzanakis I, Stamataki E, Papadaki A, et al. Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. Int Urol Nephrol. 2014;46:2199–2205.
   PubMed Web of Science ®Google Scholar
• Wilson R, Zhang P, Smyth M, et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin. 2009;25(12):3021–3028.
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137.
   PubMed Web of Science ®Google Scholar
• Chertow G, Burke S, Raggi P. Treat to goal working group. sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–252.
   PubMed Web of Science ®Google Scholar
• Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium free phosphate binder and calcium carbonate—phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62:104–115.
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J AmSoc Nephrol. 2008;19:405–412.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 2012;7:487–493.
   PubMed Web of Science ®Google Scholar
• Di Iorio B, Molony D, Bell C, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62:771–778.
   PubMed Web of Science ®Google Scholar
• Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate renagel evaluation-2 (CARE-2) study. Am J Kidney Dis. 2008;51:952–965.
   PubMed Web of Science ®Google Scholar
• Navaneethan S, Palmer S, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011;2; Art. No.: CD006023.
   Google Scholar
• Palmer S, Gardner S, Tonelli M, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691–702.
   PubMed Web of Science ®Google Scholar
• Patel L, Bernard L, Elder G. Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11:232–244.
   PubMed Web of Science ®Google Scholar
• Habbous S, Przech S, Acedillo R, et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(1):111–125.
   PubMed Web of Science ®Google Scholar
• Peter W, Wazny L, Weinhandl E, et al. A review of phosphate binders in chronic kidney disease: incremental progress or just higher costs? Drugs. 2017;77(11):1155–1186.
   PubMed Web of Science ®Google Scholar
• The COMBINE Study. The CKD optimal management with BInders and NicotinamidE (COMBINE). [ cited 2018 Jan 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02258074
   Google Scholar
• The NOPHOS Trial. Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with hyperphosphatemia. [ cited 2018 Jan 31]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000488-95/AT
   Google Scholar